Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The price of Cidara Therapeutics Inc (NASDAQ: CDTX) closed at $49.03 in the last session, up 0.66% from day before closing price of $48.71. In other words, the price has increased by $0.66 from its previous closing price. On the day, 0.84 million shares were traded. CDTX stock price reached its highest trading level at $49.25 during the session, while it also had its lowest trading level at $45.01.
Ratios:
We take a closer look at CDTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.87 and its Current Ratio is at 3.87. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
On March 12, 2025, Citizens JMP started tracking the stock assigning a Mkt Outperform rating and target price of $46.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 26 ’25 when RA CAPITAL MANAGEMENT, L.P. bought 2,272,727 shares for $44.00 per share. The transaction valued at 99,999,988 led to the insider holds 3,365,523 shares of the business.
Mineo Chrysa bought 2,270 shares of CDTX for $49,281 on Jun 02 ’25. The Director now owns 2,270 shares after completing the transaction at $21.71 per share. On Jun 03 ’25, another insider, Mineo Chrysa, who serves as the Director of the company, bought 1,050 shares for $23.44 each. As a result, the insider paid 24,614 and bolstered with 3,320 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDTX now has a Market Capitalization of 1025923328 and an Enterprise Value of 466283072. For the stock, the TTM Price-to-Sale (P/S) ratio is 3614.76 while its Price-to-Book (P/B) ratio in mrq is 4.23. Its current Enterprise Value per Revenue stands at 1543.984 whereas that against EBITDA is -4.326.
Stock Price History:
The Beta on a monthly basis for CDTX is 1.14, which has changed by 3.0320725 over the last 52 weeks, in comparison to a change of 0.11937654 over the same period for the S&P500. Over the past 52 weeks, CDTX has reached a high of $56.83, while it has fallen to a 52-week low of $10.14. The 50-Day Moving Average of the stock is 88.04%, while the 200-Day Moving Average is calculated to be 141.66%.
Shares Statistics:
According to the various share statistics, CDTX traded on average about 486.89K shares per day over the past 3-months and 2228950 shares per day over the past 10 days. A total of 22.12M shares are outstanding, with a floating share count of 13.09M. Insiders hold about 40.83% of the company’s shares, while institutions hold 31.50% stake in the company. Shares short for CDTX as of 1749772800 were 648282 with a Short Ratio of 1.33, compared to 1747267200 on 445327. Therefore, it implies a Short% of Shares Outstanding of 648282 and a Short% of Float of 5.0100001999999995.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Investors are keenly observing as 6.0 analysts analyze and rate the current performance of Cidara Therapeutics Inc (CDTX) in the stock market.The consensus estimate for the next quarter is -$1.73, with high estimates of -$1.25 and low estimates of -$2.8.
Analysts are recommending an EPS of between -$5.68 and -$9.31 for the fiscal current year, implying an average EPS of -$7.24. EPS for the following year is -$7.82, with 6.0 analysts recommending between -$5.3 and -$9.92.
